B. Riley reissued their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a report issued on Monday morning. B. Riley currently has a $220.00 price objective on the biopharmaceutical company’s stock.

ALNY has been the topic of a number of other reports. JMP Securities raised their price target on Alnylam Pharmaceuticals from $101.00 to $128.00 and gave the company an outperform rating in a report on Wednesday, September 20th. Barclays raised their price target on Alnylam Pharmaceuticals from $127.00 to $158.00 and gave the company an overweight rating in a report on Wednesday, November 8th. Piper Jaffray Companies reissued an overweight rating and set a $110.00 price target (down from $126.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 7th. FBR & Co started coverage on Alnylam Pharmaceuticals in a report on Monday, October 30th. They set a buy rating and a $150.00 price target on the stock. Finally, Cowen reaffirmed an outperform rating and issued a $151.00 target price (up from $117.00) on shares of Alnylam Pharmaceuticals in a report on Friday, November 3rd. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and sixteen have issued a buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $121.85.

Shares of Alnylam Pharmaceuticals (NASDAQ ALNY) opened at $124.86 on Monday. The company has a quick ratio of 9.83, a current ratio of 9.83 and a debt-to-equity ratio of 0.14. Alnylam Pharmaceuticals has a twelve month low of $35.98 and a twelve month high of $147.63.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.23) by ($0.11). The business had revenue of $17.10 million for the quarter, compared to the consensus estimate of $28.15 million. Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. Alnylam Pharmaceuticals’s revenue was up 24.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.21) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals will post -5.21 earnings per share for the current year.

In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $130.00, for a total transaction of $2,600,000.00. Following the sale, the director now directly owns 20,000 shares of the company’s stock, valued at $2,600,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO John Maraganore sold 74,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $126.86, for a total value of $9,387,640.00. Following the transaction, the chief executive officer now owns 223,710 shares of the company’s stock, valued at approximately $28,379,850.60. The disclosure for this sale can be found here. Insiders have sold 393,212 shares of company stock worth $48,109,436 over the last three months. 4.30% of the stock is currently owned by insiders.

Several large investors have recently made changes to their positions in the business. State of Wisconsin Investment Board boosted its position in shares of Alnylam Pharmaceuticals by 0.7% during the second quarter. State of Wisconsin Investment Board now owns 15,012 shares of the biopharmaceutical company’s stock valued at $1,197,000 after buying an additional 100 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Alnylam Pharmaceuticals by 7.0% during the second quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 167 shares during the period. Utah Retirement Systems boosted its position in shares of Alnylam Pharmaceuticals by 1.5% during the second quarter. Utah Retirement Systems now owns 13,800 shares of the biopharmaceutical company’s stock valued at $1,100,000 after buying an additional 200 shares during the period. Prudential Financial Inc. boosted its position in shares of Alnylam Pharmaceuticals by 4.8% during the second quarter. Prudential Financial Inc. now owns 4,404 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 200 shares during the period. Finally, Alliancebernstein L.P. boosted its position in shares of Alnylam Pharmaceuticals by 0.8% during the second quarter. Alliancebernstein L.P. now owns 47,873 shares of the biopharmaceutical company’s stock valued at $3,818,000 after buying an additional 398 shares during the period. Institutional investors and hedge funds own 88.43% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Alnylam Pharmaceuticals (ALNY) Earns Buy Rating from B. Riley” was reported by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at https://www.watchlistnews.com/alnylam-pharmaceuticals-alny-earns-buy-rating-from-b-riley/1763054.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.